MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ocugen, Inc. - Common Stock (NQ:OCGN)

1.370 -0.040 (-2.84%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,903,841
Open 1.420
Bid (Size) 1.370 (4,400)
Ask (Size) 1.380 (1,900)
Prev. Close 1.410
Today's Range 1.360 - 1.420
52wk Range 1.000 - 2.725
Shares Outstanding 257,328,085
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Ocugen to Participate in Upcoming September Investor and Industry Conferences
From Ocugen
Via GlobeNewswire
News headline image
Ocugen Targets 2027 BLA Filings as Gene Therapy Programs Near Key Readouts ↗
Ocugen (NASDAQ:OCGN) is positioning its ophthalmology gene therapy portfolio around treatments for inherited retinal diseases and dry age-related macular degeneration, with pivotal-stage programs in... 
Via MarketBeat

Performance

YTD
-0.7%
-0.7%
1 Month
+10.5%
+10.5%
3 Month
-2.8%
-2.8%
6 Month
-26.7%
-26.7%
1 Year
+31.7%
+31.7%

More News

Read More
News headline image
Ocugen (OCGN) Q2 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings Retirement
News headline image
Ocugen Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
Ocugen (NASDAQ:OCGN) Falls on Mixed Q2 Results as Revenue Beat Offsets Wider Loss ↗
Via Chartmill
Ocugen (NASDAQ:OCGN) Beats Q1 Revenue Estimates but Widens Net Loss, Announces $115M Capital Raise to Fund Pipeline Through 2028 ↗
Via Chartmill
News headline image
Ocugen Provides Business Update with Second Quarter 2026 Financial Results
From Ocugen
Via GlobeNewswire
News headline image
Ocugen to Participate in Upcoming August Investor Conferences
From Ocugen
Via GlobeNewswire
News headline image
Ocugen Announces that the U.S. Food and Drug Administration Has Granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Geographic Atrophy, Secondary to Dry Age-Related Macular Degeneration
From Ocugen
Via GlobeNewswire
News headline image
Ocugen to Host Conference Call on Thursday, August 6 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2026 Financial Results
From Ocugen
Via GlobeNewswire
News headline image
Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa
From Ocugen
Via GlobeNewswire
News headline image
Ocugen Eyes 3 Retinal Gene Therapy Filings as Late-Stage Pipeline Advances ↗
Via MarketBeat
News headline image
Ocugen to Participate in Upcoming July Industry Conferences
From Ocugen
Via GlobeNewswire
News headline image
Ocugen to Participate in Upcoming June Investor and Industry Conferences
From Ocugen
Via GlobeNewswire
News headline image
Ocugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior Notes
From Ocugen
Via GlobeNewswire
News headline image
3 Reasons Not to Buy Into the Hantavirus-Related Biotech Rally ↗
Via The Motley Fool
News headline image
Ocugen to Participate in Upcoming May Scientific and Investor Conferences
From Ocugen
Via GlobeNewswire
News headline image
Ocugen Provides Business Update with First Quarter 2026 Financial Results
From Ocugen
Via GlobeNewswire
News headline image
Ocugen, Inc. Announces Pricing of $115 Million of 6.75% Convertible Senior Notes
From Ocugen
Via GlobeNewswire
Top movers in Monday's after hours session ↗
Via Chartmill
News headline image
Ocugen Announces Private Offering of $115 Million of Convertible Senior Notes
From Ocugen
Via GlobeNewswire
News headline image
Ocugen to Host Conference Call on Tuesday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2026 Financial Results
From Ocugen
Via GlobeNewswire
News headline image
Ocugen to Present at April 2026 Investor and Industry Conferences
From Ocugen
Via GlobeNewswire
News headline image
Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease
From Ocugen
Via GlobeNewswire
News headline image
Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
From Ocugen
Via GlobeNewswire

Frequently Asked Questions

Is Ocugen, Inc. - Common Stock publicly traded?
Yes, Ocugen, Inc. - Common Stock is publicly traded.
What exchange does Ocugen, Inc. - Common Stock trade on?
Ocugen, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Ocugen, Inc. - Common Stock?
The ticker symbol for Ocugen, Inc. - Common Stock is OCGN on the Nasdaq Stock Market
What is the current price of Ocugen, Inc. - Common Stock?
The current price of Ocugen, Inc. - Common Stock is 1.370
When was Ocugen, Inc. - Common Stock last traded?
The last trade of Ocugen, Inc. - Common Stock was at 08/27/26 04:00 PM ET
What is the market capitalization of Ocugen, Inc. - Common Stock?
The market capitalization of Ocugen, Inc. - Common Stock is 352.54M
How many shares of Ocugen, Inc. - Common Stock are outstanding?
Ocugen, Inc. - Common Stock has 353M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story